Chikako Shimokawa

Dr. Chikako Shimokawa

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSChikako Shimokawa
Chikako Shimokawa
TKTamotsu Kato
Tamotsu Kato
TTTadashi Takeuchi
Tadashi Takeuchi
NONoriyasu Ohshima
Noriyasu Ohshima
TFTakao Furuki
Takao Furuki
HHHajime Hisaeda
Hajime Hisaeda
Type 1 diabetes (T1D) is an autoimmune disease in which insulin-producing pancreatic β-cells are destroyed. Intestinal helminths can cause asymptomatic chronic and immunosuppressive infections and suppress disease in rodent models of T1D. However, the underlying regulatory mechanisms for this protection are unclear. Here, we report that CD8+regulatory T (Treg) cells prevent the onset of streptozotocin -induced diabetes by a rodent intestinal nematode. Trehalose derived from nematodes affects the intestinal microbiota and increases the abundance ofRuminococcusspp., resulting in the induction of CD8+Treg cells. Furthermore, trehalose has therapeutic effects on both streptozotocin-induced diabetes and in the NOD mouse model of T1D. In addition, compared with healthy volunteers, patients with T1D have fewer CD8+Treg cells, and the abundance of intestinalRuminococcuspositively correlates with the number of CD8+Treg cells in humans.

6 February 2020 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
SOSeiji Obi
Seiji Obi
CSChikako Shimokawa
Chikako Shimokawa
MKMizuki Katsuura
Mizuki Katsuura
AOAlex Olia
Alex Olia
Takashi ImaiTakashi Imai
Takashi Imai
HHHajime Hisaeda
Hajime Hisaeda

1 December 2020 in International Journal for Parasitology
Verified
Journal Article
Closed access
HNHa Ngo-Thanh
Ha Ngo-Thanh
TSTsutomu Sasaki
Tsutomu Sasaki
KSKazutomo Suzue
Kazutomo Suzue
HYHideaki Yokoo
Hideaki Yokoo
KIKoji Isoda
Koji Isoda
Takashi ImaiTakashi Imai
Takashi Imai

2 November 2024 in Parasitology International
Verified
Journal Article
Open access
CSChikako Shimokawa
Chikako Shimokawa
The global prevalence of autoimmune diseases has surged in recent decades. Consequently, environmental triggers have emerged as crucial contributors to autoimmune diseases, equally relevant to classical risk factors, such as genetic polymorphisms, infections, and smoking. Sequencing-based approaches have demonstrated distinct gut microbiota compositions in individuals with autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus (T1D), and systemic lupus erythematosus, compared to healthy controls. Furthermore, fecal microbiota transplantation and microbial inoculation experiments have supported the hypothesis that alterations in the gut microbiota can influence autoimmune responses and disease outcomes. Herein, we propose that intestinal helminths may serve as a critical factor in inducing alterations in the gut microbiota. The concept of helminth-mediated suppression of autoimmune diseases in humans is supported by substantial evidence, aligning with the long-standing "hygiene hypothesis." This review focused on T1D to explore the interactions between parasites, gut microbiota, and the immune system-a topic that remains a black box within this intricate triangular relationship.

11 July 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
Takashi ImaiTakashi Imai
Takashi Imai
KSKazutomo Suzue
Kazutomo Suzue
HNHa Ngo-Thanh
Ha Ngo-Thanh
CSChikako Shimokawa
Chikako Shimokawa
HHHajime Hisaeda
Hajime Hisaeda
Human malaria vaccine trials have revealed vaccine efficacy but improvement is still needed. In this study, we aimed to re-evaluate vaccination with blood-stage naturally attenuated parasites, as a whole-organism vaccine model against cross-strain and cross-species malaria, to establish a better vaccination strategy. C57BL/6 mice controlled blood-stage Plasmodium yoelii 17XNL (PyNL) within 1 month of infection, while mice with a variety of immunodeficiencies demonstrated different susceptibilities to PyNL, including succumbing to hyperparasitemia. However, after recovery, survivors had complete protection against a challenge with the lethal strain PyL. Unlike cross-strain protection, PyNL-recovered mice failed to induce sterile immunity against Plasmodium berghei ANKA, although prolonged survival was observed in some vaccinated mice. Splenomegaly is a typical characteristic of malaria; the splenic structure became reorganized to prioritize extra-medullary hematopoiesis and to eliminate parasites. We also found that the peritoneal lymph node was enlarged, containing activated/memory phenotype cells that did not confer protection against PyL challenge. Hemozoins remained in the spleen several months after PyNL infection. Generation of an attenuated human blood-stage parasite expressing proteins from multiple species of malaria would greatly improve anti-malaria vaccination.

11 April 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
CSChikako Shimokawa
Chikako Shimokawa
WMWakana Mizutani
Wakana Mizutani
HMHaruhisa Motegi
Haruhisa Motegi
NGNaomi Gokan
Naomi Gokan
JTJunichi Tomita
Junichi Tomita
HHHajime Hisaeda
Hajime Hisaeda
Obesity is a major global health issue, and novel dietary approaches are needed for prevention and management. This study investigates the effect of insoluble konjac glucomannan (iKGM) derived from edible konnyaku, a traditional Japanese food, on weight gain suppression in mice. Mice treated with iKGM showed increased fecal volume, reduced food intake, and suppressed weight gain (Day 21; p < 0.01). This weight-suppression effect was prebiotic rather than physical properties of iKGM, as antibiotic treatment abolished the weight-suppressing effect despite increased fecal volume. iKGM treatment altered the gut microbiota, notably increasing Akkermansia muciniphila (Day 21; p < 0.01), a bacterium associated with weight loss, along with elevated levels of short-chain fatty acids (SCFAs) such as butyrate and propionate (Day 21; p < 0.01). Furthermore, iKGM-induced weight suppression was linked to elevated leptin levels (Day 21; p < 0.01), an appetite suppressant induced by SCFAs. These results suggest that iKGM modulates gut microbiota, increases A. muciniphila, induces leptin production, and reduces food intake, inhibiting weight gain. This study indicates that iKGM may represent a promising approach for obesity prevention through gut microbiota modulation. Future research should investigate the mechanisms of iKGM’s effects on microbiota and explore its long-term safety and efficacy in clinical trials.